{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:47:55Z","timestamp":1779896875586,"version":"3.53.1"},"reference-count":64,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Background: Hepatitis C virus infection remains common in patients with chronic kidney disease, including those on maintenance dialysis. The relationship between hepatitis C virus infection and chronic kidney disease is bi-directional; in fact, HCV is both a cause and consequence of chronic kidney disease. According to a systematic review with meta-analysis of observational studies (n = 23 studies) (n = 574,081 patients on long-term dialysis), anti-HCV positive serologic status was an independent and significant risk factor for death in patients with advanced chronic kidney disease on long-term dialysis. The overall estimate for adjusted mortality (all-cause death risk) with HCV was 1.26 (95% CI, 1.18; 1.34) (p &lt; 0.0001). Interferon-based therapies are biased by low efficacy\/safety in chronic kidney disease, but the advent of direct-acting antiviral drugs has made a paradigm shift in the treatment of HCV-infection. These medications give interruption of viral replication because they target specific non-structural viral proteins; four classes of DAAs exist-NS3\/4A protease inhibitors, NS5A inhibitors, NS5B nucleoside and non-nucleoside polymerase inhibitors. All-oral, interferon-free, ribavirin-free combinations of DAAs are now available. Aim: The goal of this narrative review is to report the available treatment options for HCV in advanced chronic kidney disease. Methods: We have made an extensive review of the medical literature and various research engines have been adopted. Results: Some combinations of DAAs are currently recommended for HCV in advanced CKD (including patients on maintenance dialysis): elbasvir\/grazoprevir; glecaprevir\/pibrentasvir; and sofosbuvir-based regimens. Solid evidence, based on registration and \u201creal life\u201d studies supports their efficacy (SVR rates &gt; 90%) and safety even in patients with advanced CKD. No dosage adjustment is necessary and treatment duration is 8\u201312 weeks. However, recent data highlight that many patients with advanced CKD remain untreated, and numerous barriers to antiviral treatment of HCV still exist. Whether successful antiviral therapy with DAAs will translate into improved survival in the advanced CKD population is another point of future research.<\/jats:p>","DOI":"10.3390\/pathogens10111381","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T23:54:33Z","timestamp":1635292473000},"page":"1381","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease"],"prefix":"10.3390","volume":"10","author":[{"given":"Fabrizio","family":"Fabrizi","sequence":"first","affiliation":[{"name":"Division of Nephrology, Dialysis, and Kidney Transplant, Ca\u2019 Granda IRCCS Foundation and Maggiore Policlinico Hospital, 20122 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Cerutti","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Dialysis, and Kidney Transplant, Ca\u2019 Granda IRCCS Foundation and Maggiore Policlinico Hospital, 20122 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Messa","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Dialysis, and Kidney Transplant, Ca\u2019 Granda IRCCS Foundation and Maggiore Policlinico Hospital, 20122 Milano, Italy"},{"name":"Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.clinre.2018.10.009","article-title":"Hepatitis C virus and mortality among patients on dialysis: A systematic review and meta-analysis","volume":"43","author":"Fabrizi","year":"2019","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.kint.2018.11.038","article-title":"Prevalence, incidence, and risk factors for hepatitis C virus infection in haemodialysis patients","volume":"95","author":"Jadoul","year":"2019","journal-title":"Kidney Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/sdi.12762","article-title":"Direct-acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease","volume":"32","author":"Bruchfeld","year":"2019","journal-title":"Semin. Dial."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group (2018). KDIGO 2018 clinical practice guideline for the Prevention, Diagnosis, Evaluation and Treatment of hepatitis C in chronic kidney disease. Kidney Int., 8, 91\u2013165.","DOI":"10.1016\/j.kisu.2018.06.001"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1111\/j.1523-1755.2004.00649.x","article-title":"Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS","volume":"65","author":"Fissell","year":"2004","journal-title":"Kidney Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cld.2009.11.011","article-title":"Health care-associated transmission of hepatitis B and C viruses in hemodialysis units","volume":"14","author":"Fabrizi","year":"2010","journal-title":"Clin. Liver Dis."},{"key":"ref_7","first-page":"51","article-title":"Hepatitis C in the Russian Federation: Challenges and future directions","volume":"8","author":"Mukolomov","year":"2016","journal-title":"Hepatic Med. Evid. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/jmv.23581","article-title":"Hepatitis B and C virus infection among hemodialysis patients in Yogyakarta, Indonesia: Prevalence and molecular evidence for nosocomial transmission","volume":"85","author":"Rinonce","year":"2016","journal-title":"J. Med. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Jakupi, X., Mlakar, J., Lunar, M., Seme, K., Rudhani, I., Raka, L., Vince, A., and Poljak, M. (2018). A very high prevalence of hepatitis C virus infection among patients undergoing hemodialysis in Kosovo: A nationwide study. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-1100-5"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jceh.2019.11.002","article-title":"Incidence and risk factors for hepatitis C virus and hepatitis B virus seroconversion in end-stage renal failure patients on maintenance hemodialysis","volume":"10","author":"Kataruka","year":"2020","journal-title":"J. Clin. Exp. Hepat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5582\/ddt.2019.01044","article-title":"Profile and predictors of hepatitis and HIV infection in patients on hemodialysis of Quetta, Pakistan","volume":"13","author":"Lodhi","year":"2019","journal-title":"Drug Discov. Ther."},{"key":"ref_12","first-page":"644","article-title":"Prevalence of hepatitis C among haemodialysis patients in a tertiary care hospital in south India","volume":"12","author":"Madhavan","year":"2020","journal-title":"Iran. J. Microbiol."},{"key":"ref_13","first-page":"109","article-title":"Infection with hepatitis C virus in haemodialysis patients: An overview of the diagnosis and prevention rules within a haemodialysis center (review)","volume":"20","author":"Timofte","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e1147","DOI":"10.1002\/mbo3.1147","article-title":"Circulation of an atypical hepatitis C virus (HCV) strain at a dialysis unit in northeast India","volume":"10","author":"Kalita","year":"2021","journal-title":"Microbiol. Open"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/njcp.njcp_464_19","article-title":"Prevalence and risk factors for hepatitis B and C among end-stage renal disease patients on haemodialysis in Gaborone, Botswana","volume":"24","author":"Mahupe","year":"2021","journal-title":"Niger. J. Clin. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1159\/000045215","article-title":"Quantitative assessment of HCV load in chronic hemodialysis patients: A cross-sectional survey","volume":"80","author":"Fabrizi","year":"1998","journal-title":"Nephron"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41581-018-0081-8","article-title":"Hepatitis C virus and the kidney","volume":"15","author":"Pol","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.7326\/0003-4819-159-11-201312030-00005","article-title":"Pegylated interferon-alpha 2a with or without low-dose ribavirin for treatment \u2013na\u00efve patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial","volume":"159","author":"Liu","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/gutjnl-2014-307080","article-title":"Peginterferon alfa-2a with or without low-dose ribavirin for treatmend \u2013na\u00efve patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomized trial","volume":"64","author":"Liu","year":"2015","journal-title":"Gut"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/1744-9987.12318","article-title":"Pegylated interferon monotherapy of chronic hepatitis C in the dialysis population: Systematic review and meta-analysis","volume":"19","author":"Fabrizi","year":"2015","journal-title":"Apher. Dial."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/jvh.12276","article-title":"Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: Meta-analysis of clinical studies","volume":"21","author":"Fabrizi","year":"2014","journal-title":"J. Viral. Hepat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2215\/CJN.07940716","article-title":"Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis","volume":"12","author":"Goodkin","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment na\u00efve and treatment experienced patients with hepatitis C virus genotype infection and stage 4\u20135 chronic kidney disease (the C \u2013SURFER study): A combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2468-1253(17)30116-4","article-title":"Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4\u20135 chronic kidney disease: Clinical, virological, and health-related quality of life outcomes from a phase 3, multicenter, randomized, double-blind, placebo-controlled trial","volume":"2","author":"Bruchfeld","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/liv.14320","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection","volume":"40","author":"Lawitz","year":"2020","journal-title":"Liver Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of direct-acting antiviral combinations for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_28","unstructured":"Vierling, J., Lawitz, E., Reddy, R., Cohen, E., Kemmer, N., Morelli, G., Zamor, P., Bennett, M., Bernstein, D., and Kowdley, K. (2016, January 11\u201315). RUBY-I, Safety and efficacy of ombitasvir\/paritaprevir\/ritonavir and dasabuvir with or without ribavirin in adults with genotype 1 chronic hepatitis C virus infection with severe renalm impairment or end stage renal disease. Proceedings of the AASLD 67th Annual Meeting, Boston, MA, USA."},{"key":"ref_29","unstructured":"Gane, E., Sol\u00e0, R., Cohen, E., Roberts, S., George, J., Skoien, R., Riordan, S., Mobashery, N., Abunimeh, M., and Cohen, D. (2016, January 11\u201315). RUBY-II study: Ombitasvir\/paritaprevir\/ritonavir\u00b1dasabuvir for HCV genotype 1a or 4 with severe renal impairment. Proceedings of the AASLD 67th Annual Meeting, Boston, MA, USA."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3233\/JRS-2012-0574","article-title":"Sponsorship bias in clinical research","volume":"24","author":"Lexchin","year":"2012","journal-title":"Int. J. Risk Saf. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1111\/apt.14635","article-title":"Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: Retrospective analyses from the TRIO network","volume":"47","author":"Flamm","year":"2018","journal-title":"Aliment. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/0391398818763478","article-title":"\u2018Real life\u2019 experience with direct-acting antiviral agents for hepatitis C virus in end stage renal disease","volume":"41","author":"Fabrizi","year":"2018","journal-title":"Int. J. Artif. Organs"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.antiviral.2018.10.003","article-title":"Kyushu University Liver Disease Study (KULDS) Group. Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real \u2013world cohort study focusing on chronic kidney disease","volume":"159","author":"Ogawa","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.5009\/gnl19393","article-title":"Real-life effectiveness and safety of glecaprevir\/pibrentasvir for Korean patients with chronic hepatitis C at a single institution","volume":"15","author":"Park","year":"2021","journal-title":"Gut Liver"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Stein, K., Albrecht, S., Hartwig, K., Gerlinde, T., Uwe, N., Christine, J., Heyne, R., Serfert, Y., Niedereau, C., and Zeuzem, S. (2020). German Hepatitis C-Registry. Hepatitis C therapy with grazoprevir\/elbasvir and glecaprevir\/pibrentasvir in patients with advanced chronic kidney disease; data from the German Hepatitis C-Registry (DHC-R). Eur. J. Gastroenterol. Hepatol.","DOI":"10.1055\/s-0040-1716035"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jvh.12664","article-title":"Therapy with ombitasvir\/paritaprevir\/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicenter experience","volume":"24","author":"Rincon","year":"2017","journal-title":"J. Viral Hepat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1111\/jgh.14672","article-title":"Paritaprevir\/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis","volume":"34","author":"Liu","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00535-019-01556-y","article-title":"NORTE Study Group. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection","volume":"54","author":"Suda","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/jgh.14447","article-title":"Efficacy and safety of elbasvir\/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study","volume":"34","author":"Atsukawa","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.kint.2018.02.019","article-title":"Grazoprevir plus elbasvir in HCV genotype -1 or -4 infected patients with stage 4\/5 severe chronic kidney disease is safe and effective","volume":"94","author":"Alric","year":"2018","journal-title":"Kidney Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9180","DOI":"10.1038\/s41598-020-66182-8","article-title":"Elbasvir\/grazoprevir for hepatitis C virus genotype 1b East\u2014Asian patients receiving hemodialysis","volume":"10","author":"Liu","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/apt.15218","article-title":"The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: A prospective multicenter study","volume":"49","author":"Atsukawa","year":"2019","journal-title":"Aliment. Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jvh.13265","article-title":"Glecaprevir\/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment","volume":"27","author":"Liu","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Yen, H., Su, P., Zeng, Y., Liu, I., Huang, S., Hsu, Y., Chen, Y., Yang, C., Wu, S., and Chou, K. (2020). Glecaprevir-pibrentasvir for chronic hepatitis C; comparing treatment effect in patients with and without end-stage renal disease in a real world setting. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0237582"},{"key":"ref_45","first-page":"78","article-title":"NORTE Study Group","volume":"54","author":"Suda","year":"2019","journal-title":"Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1 hepatitis C virus infection. J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S2468-1253(19)30417-0","article-title":"Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: A multicenter, phase 2b, non-randomised, open-label study","volume":"5","author":"Lawitz","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.14309\/ajg.0000000000001281","article-title":"Ledipasvir\/sofosbuvir for 8, 12, or 24 weeks in hepatitis C patients undergoing dialysis for end-stage renal disease","volume":"116","author":"Chuang","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin. Pharm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.nefro.2021.01.008","article-title":"Sofosbuvir-based regimens for HCV in stage 4\u20135 chronic kidney disease: A systematic review with meta-analysis","volume":"41","author":"Fabrizi","year":"2021","journal-title":"Nefrologia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12985-019-1140-x","article-title":"Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4\u20135 chronic kidney disease: A systematic review and meta-analysis","volume":"16","author":"Li","year":"2019","journal-title":"Virol. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jceh.2019.10.004","article-title":"Sofosbuvir-velpatasvir fixed drug combination for the treatment of chronic hepatitis C infection in patients with end-stage renal disease and kidney transplantation","volume":"10","author":"Gaur","year":"2020","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/apt.14799","article-title":"Effectiveness, treatment completion and safety of sofosbuvir\/ledipasvir and paritaprevir\/ritonavir\/ombitasvir+dasabuvir in patients with chronic kidney disease: An ERCHIVES study","volume":"48","author":"Butt","year":"2018","journal-title":"Aliment. Pharm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jhep.2015.06.004","article-title":"Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease","volume":"63","author":"Bhamidimarri","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/jvh.12983","article-title":"Sofosbuvir with NS5a inhibitors in hepatitis C virus infection with severe renal insufficiency","volume":"25","author":"Singh","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/liv.14299","article-title":"Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment","volume":"40","author":"Eletreby","year":"2020","journal-title":"Liver Int."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s12072-018-9859-9","article-title":"Efficacy and safety of ledipasvir\/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment","volume":"12","author":"Okubo","year":"2018","journal-title":"Hepatol. Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/liv.14685","article-title":"Sofosbuvir and velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance hemodialysis","volume":"41","author":"Taneja","year":"2021","journal-title":"Liver Int."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Liu, C., Chen, C., Su, W., Tseng, K., Lo, C., Liu, C., Chen, J., Peng, C., Shih, Y., and Yang, S. (2021). Sofosbuvir\/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. Gut.","DOI":"10.1136\/gutjnl-2020-323569"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S433","DOI":"10.1016\/S0168-8278(12)61113-1","article-title":"The effect of renal impairment and end stage renal disease on the single dose pharmacokinetics of PSI-7977","volume":"56","author":"Compropst","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","volume":"65","author":"Desnoyer","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_62","unstructured":"AASLD\/IDSA (2021, September 29). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Patients with Renal Impairment. Available online: https:\/\/www.hcvguidelines.org."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1053\/j.ajkd.2021.03.017","article-title":"Elimination of hepatitis C virus in a dialysis population: A collaborative care model in Taiwan","volume":"78","author":"Hu","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"ref_64","unstructured":"WHO (2021, July 27). Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/273174\/9789241550345-eng.pdf."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/11\/1381\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:23:51Z","timestamp":1760167431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/11\/1381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":64,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["pathogens10111381"],"URL":"https:\/\/doi.org\/10.3390\/pathogens10111381","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]}}}